-
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)
Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
ELISA バッファーとレシピ(Page)ELISA バッファーとレシピ | Assay Genie | Assay Genie
Kompetitiver ELISA im Labor: Startwerte 1–10 µg/mL, Fehlerbehebung(Post)Ein kompetitiver ELISA misst Analytkonzentrationen über ein invertiertes Signal: Probeantigen und ein markierter Tracer konkurrieren um dieselben, begrenzten Bindungsstellen. Je mehr Analyt in der
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
Guide to Western Blot Sample Preparation(Post)Protein Analysis · ProtocolsWestern Blot Sample Preparation: A Practical GuideMost failed Western blots fail before the gel is loaded. Lysis buffer choice, inhibitor selection, accurate protein quanti
Citations(Page) What is RNAi? All You Need to Know(Post)Molecular Biology · Gene SilencingWhat is RNAi? A Complete Guide to RNA InterferenceRNA interference (RNAi) is a conserved biological process in which small double-stranded RNA molecules silence gene
Cytokine Storms: What happens when the immune system overreacts?(Post)Immunology · HyperinflammationCytokine Storm and Cytokine Release Syndrome: Mechanisms, Triggers and MarkersA cytokine storm is a self-amplifying inflammatory response in which cytokine release drives
cGAS-STING Signalling: Pathway, Regulation and Key Assays(Post)Double-stranded DNA in the cytosol is always a mistake. A virus has uncoated, a mitochondrion has ruptured, a micronucleus has burst, or a chromosome has been broken and left unrepaired. cGAS treats
Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols (Post)Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols What is COVID-19? COVID-19, the disea
Lacnotuzumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec
Sepsis and Immune Dysregulation(Post)Exploring sepsis: a critical imbalance in the immune response to infection. Key Takeaways: Sepsis is a severe, immune-driven response to infection causing systemic inflammation and potent
In the Thymus, Co-stimulation Kills(Post)In the periphery, co-stimulation rescues a T cell. In the thymus, the same molecules kill it. A peripheral T cell that engages its receptor without CD80 and CD86 becomes anergic; engage them and it r
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Cyclins and Cyclin Dependent Kinase – Review(Post)Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa
Canine Multiplex ELISA Panels(Page)Canine Multiplex ELISA & Cytokine Assay Panels | Assay Genie
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.